ScreenerHero

IGC IGC Pharma, Inc.

AMEX · US · Healthcare · Biotechnology · igcpharma.com
0.2800USD0.00%Mkt Cap: 28.95M $P/E: —

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap28.95M USD
Enterprise Value29.68M USD
Revenue (TTM)1.11M USD
Gross Profit619.00K USD
Net Income (TTM)-7.12M USD
Revenue/Share0.01 USD
Last Price0.2800 USD
Fiscal Year EndMar 2025
MR QuarterJun 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.50
PEG—
EV/EBITDA-3.94
EV/Revenue26.83
P/S26.17
P/B4.67
EPS (TTM)-0.07
EPS (Forward)-0.08
52W Range
0.235021% of range0.4500
52W High0.4500 USD
52W Low0.2350 USD
Profitability
Gross Margin48.70%
Oper. Margin-1050.57%
EBITDA Margin0.00%
Profit Margin-560.27%
ROE-112.50%
ROA-81.41%
Growth
Revenue Growth-19.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.07M USD
CapEx (TTM)316.00K USD
FCF Margin-227.97%
FCF Yield-8.71%
Net Debt728.00K USD
Net Debt/EBITDA-0.10
Balance Sheet
Debt/Equity0.04
Current Ratio1.32
Quick Ratio0.79
Book Value/Sh0.06 USD
Cash/Share0.0030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 19, 2013
Analyst Consensus
Rating—
Target (Mean)6.000 USD
Upside (mean)+2042.9%
Target Range6.000 USD – 6.000 USD
# Analysts1
Ownership
Shares Out.103.38M
Float89.72M
Insiders13.17%
Institutions22.09%
Short Interest
Short Ratio1.3d
Short % Float1.77%
Short % Out.1.04%
Shares Short1.07M
Short (prev mo.)767.65K
Technical
SMA 500.2800 (+0.0%)
SMA 2000.2845 (-1.6%)
Beta0.48
S&P 52W Chg16.45%
Avg Vol (30d)868.94K
Avg Vol (10d)795.07K
Technical Indicators
RSI (14)51.0
MACD-0.0001
MACD Signal0.0007
MACD Hist.-0.0008
BB Upper0.3106 USD
BB Middle0.2843 USD
BB Lower0.2580 USD
BB Width18.50%
ATR (14)0.0143 USD
Vol Ratio (20d)0.39x